Trial Profile
Phase 2a Open-Label Pilot Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 28-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and/or 4
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2022
Price :
$35
*
At a glance
- Drugs Vadadustat (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Akebia Therapeutics
- 13 Aug 2014 New trial record